3. Fair Value Measurements 3. Contingent Consideration (Details) (USD $)		6 Months Ended						6 Months Ended									6 Months Ended									6 Months Ended
	Apr. 10, 2014 GnuBIO [Member]	Jun. 30, 2014 probability lower [Member] GnuBIO [Member]	Jun. 30, 2014 Discount Rate Lower [Member] GnuBIO [Member]	Jun. 30, 2014 Sales milestone minimum payment [Member] CellSorter [Member]	Jun. 30, 2014 Sales milestone year 1 maximum payment percentage [Member] CellSorter [Member]	Jun. 30, 2014 Sales milestone year 2 maximum payment percentage [Member] CellSorter [Member]	Jun. 30, 2014 Sales milestone year 3 maximum payment percentage [Member] CellSorter [Member]	Jun. 30, 2014 Credit Adjusted Discount Rates Lower [Member] CellSorter [Member]	Jun. 30, 2014 Credit Adjusted Discount Rate Higher [Member] CellSorter [Member]	Jun. 30, 2014 Market Price of Risk [Member] CellSorter [Member]	Jun. 30, 2014 Projected Volatility of Growth Rate [Member] CellSorter [Member]	Jun. 30, 2014 Projected Volatility of Growth Rate Higher [Member] CellSorter [Member]	Jun. 30, 2014 Probability Higher [Member] GnuBIO [Member]	Jun. 30, 2014 Sales Milestone year 1 bookings [Member] CellSorter [Member]	Jun. 30, 2014 Sales milestone year 2 bookings [Member] CellSorter [Member]	Jun. 30, 2014 Sales milestone year 3 bookings [Member] CellSorter [Member]	Jun. 30, 2014 Discount Rate Higher [Member] GnuBIO [Member]	Jun. 30, 2014 probability lower1 [Member] GnuBIO [Member]	Jun. 30, 2014 Probability Higher 1 [Member] GnuBIO [Member]	Jun. 30, 2014 Discount Rate Lower 1 [Member] GnuBIO [Member]	Jun. 30, 2014 Discount Rate Higher 1 [Member] GnuBIO [Member]	Jun. 30, 2014 Fair Value, Measurements, Recurring [Member] Estimate of Fair Value, Fair Value Disclosure [Member]		Dec. 31, 2013 Fair Value, Measurements, Recurring [Member] Estimate of Fair Value, Fair Value Disclosure [Member]		Jun. 30, 2014 Fair Value, Measurements, Recurring [Member] Estimate of Fair Value, Fair Value Disclosure [Member] CellSorter [Member]	Jun. 30, 2014 Fair Value, Measurements, Recurring [Member] Estimate of Fair Value, Fair Value Disclosure [Member] GnuBIO [Member]	Jun. 30, 2014 Fair Value, Measurements, Recurring [Member] Fair Value, Inputs, Level 1 [Member]		Dec. 31, 2013 Fair Value, Measurements, Recurring [Member] Fair Value, Inputs, Level 1 [Member]		Jun. 30, 2014 Fair Value, Measurements, Recurring [Member] Fair Value, Inputs, Level 2 [Member]		Dec. 31, 2013 Fair Value, Measurements, Recurring [Member] Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, at Fair Value	$ 10,700,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low				0
(Decrease) increase in fair value of contingent consideration included in SGA																										(5,400,000)	10,700,000
Contingent Consideration at Fair Value																						26,100,000	[1]	20,800,000	[1]	15,400,000		0	[1]	0	[1]	0	[1]	0	[1]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 70,000,000													$ 20,000,000	$ 30,000,000	$ 45,000,000
Business Acquisition, Contingent Consideration, Potential Percentage Payout					60.00%	51.32%	50.38%
Contingent Consideration Level 3 Inputs		0.75	.0067					0.0042	0.0129	.0125	0.08	0.2	.422				.0083	.00001	0	.011	.022

[1] Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2014 December 31, 2013Other current liabilities$2.7 $6.1Other long-term liabilities23.4 14.7 Total$26.1 $20.8